<?xml version="1.0"?>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>Peptide-based vaccine successfully induces protective immunity against canine visceral leishmaniasis</dc:title>
  <dc:creator>/Petitdidier, Elodie</dc:creator>
  <dc:creator>/Pagniez, Julie</dc:creator>
  <dc:creator>Pissarra, J.</dc:creator>
  <dc:creator>Holzmuller, P.</dc:creator>
  <dc:creator>Papierok, G.</dc:creator>
  <dc:creator>Vincendeau, P.</dc:creator>
  <dc:creator>/Lemesre, Jean-Loup</dc:creator>
  <dc:creator>/Bras Goncalves, Rachel</dc:creator>
  <dc:description>Dogs are the main reservoir of zoonotic visceral leishmaniasis. Vaccination is a promising approach to help control leishmaniasis and to interrupt transmission of the Leishmania parasite. The promastigote surface antigen (PSA) is a highly immunogenic component of Leishmania excretory/secretory products. A vaccine based on three peptides derived from the carboxy-terminal part of Leishmania amazonensis PSA and conserved among Leishmania species, formulated with QA-21 as adjuvant, was tested on naive Beagle dogs in a preclinical trial. Four months after the full course of vaccination, dogs were experimentally infected with Leishmania infantum promastigotes. Immunization of dogs with peptide-based vaccine conferred immunity against experimental infection with L. infantum. Evidence for macrophage nitric oxide production and anti-leishmanial activity associated with IFN-y production by lymphocytes was only found in the vaccinated group. An increase in specific IgG2 antibodies was also measured in vaccinated dogs from 2 months after immunization. Additionally, after challenge with L. infantum, the parasite burden was significantly lower in vaccinated dogs than in the control group. These data strongly suggest that this peptide-based vaccine candidate generated cross-protection against zoonotic leishmaniasis by inducing a Th1-type immune response associated with production of specific IgG2 antibodies. This preclinical trial including a peptide-based vaccine against leishmaniasis clearly demonstrates effective protection in a natural host. This approach deserves further investigation to enhance the immunogenicity of the peptides and to consider the possible engineering of a vaccine targeting several Leishmania species.</dc:description>
  <dc:date>2019</dc:date>
  <dc:type>text</dc:type>
  <dc:identifier>https://www.documentation.ird.fr/hor/fdi:010077468</dc:identifier>
  <dc:identifier>fdi:010077468</dc:identifier>
  <dc:identifier>Petitdidier Elodie, Pagniez Julie, Pissarra J., Holzmuller P., Papierok G., Vincendeau P., Lemesre Jean-Loup, Bras Goncalves Rachel. Peptide-based vaccine successfully induces protective immunity against canine visceral leishmaniasis. 2019, 4, art. 49 [9 ]</dc:identifier>
  <dc:language>EN</dc:language>
</oai_dc:dc>
